116 related articles for article (PubMed ID: 19595770)
1. Production and characterization of long-acting recombinant human albumin-EPO fusion protein expressed in CHO cell.
Joung CH; Shin JY; Koo JK; Lim JJ; Wang JS; Lee SJ; Tan HK; Kim SL; Lim SM
Protein Expr Purif; 2009 Dec; 68(2):137-45. PubMed ID: 19595770
[TBL] [Abstract][Full Text] [Related]
2. [Expression of rhEPO-L-Fc fusion protein and analysis of its bioactivity and pharmacokinetics].
Zhu Q; Huang Z; Huang Y; Qin Y
Sheng Wu Gong Cheng Xue Bao; 2008 Nov; 24(11):1874-9. PubMed ID: 19256332
[TBL] [Abstract][Full Text] [Related]
3. [Construction and expression of recombinant human serum albumin-EPO fusion protein].
Huang YC; Gou XH; Han L; Li DH; Zhao LY; Wu QQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 May; 42(3):317-21. PubMed ID: 21826990
[TBL] [Abstract][Full Text] [Related]
4. Biochemical characterization of rhEpo-Fc fusion protein expressed in CHO cells.
Schriebl K; Trummer E; Lattenmayer C; Weik R; Kunert R; Müller D; Katinger H; Vorauer-Uhl K
Protein Expr Purif; 2006 Oct; 49(2):265-75. PubMed ID: 16861003
[TBL] [Abstract][Full Text] [Related]
5. [Eukaryotic expression, purification and analysis of the fusion protein of Epo-Tpo(C)].
Wang Z; Hou Y; Yang X
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Mar; 15(1):5-8. PubMed ID: 12526292
[TBL] [Abstract][Full Text] [Related]
6. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse.
Boado RJ; Hui EK; Lu JZ; Pardridge WM
J Pharmacol Exp Ther; 2010 Jun; 333(3):961-9. PubMed ID: 20233799
[TBL] [Abstract][Full Text] [Related]
7. Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli.
Wang YJ; Liu YD; Chen J; Hao SJ; Hu T; Ma GH; Su ZG
Int J Pharm; 2010 Feb; 386(1-2):156-64. PubMed ID: 19932158
[TBL] [Abstract][Full Text] [Related]
8. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2010 Dec; 7(6):2148-55. PubMed ID: 20860349
[TBL] [Abstract][Full Text] [Related]
9. Expression, purification, and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris.
Dou WF; Lei JY; Zhang LF; Xu ZH; Chen Y; Jin J
Protein Expr Purif; 2008 Sep; 61(1):45-9. PubMed ID: 18556214
[TBL] [Abstract][Full Text] [Related]
10. The prolonged half-lives of new erythropoietin derivatives via peptide addition.
Lee DE; Son W; Ha BJ; Oh MS; Yoo OJ
Biochem Biophys Res Commun; 2006 Jan; 339(1):380-5. PubMed ID: 16314154
[TBL] [Abstract][Full Text] [Related]
11. Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans.
Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM
Bioconjug Chem; 2008 Mar; 19(3):731-9. PubMed ID: 18278853
[TBL] [Abstract][Full Text] [Related]
12. Overexpression and characterization of recombinant human fusion protein IL-6/IL-2 (CH925).
Zhao C; Tang P; Wang J; Mao N; Jiang F; Li X; Liu X; Zhang M; Ren Y; Du D
Stem Cells; 1994 May; 12(3):339-47. PubMed ID: 8075595
[TBL] [Abstract][Full Text] [Related]
13. Half-life extension through albumin fusion technologies.
Schulte S
Thromb Res; 2009 Dec; 124 Suppl 2():S6-8. PubMed ID: 20109653
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-3/erythropoietin fusion proteins: in vitro effects on hematopoietic cells.
Weich NS; Tullai J; Guido E; McMahon M; Jolliffe LK; Lopez AF; Vadas MA; Lowry PA; Quesenberry PJ; Rosen J
Exp Hematol; 1993 May; 21(5):647-55. PubMed ID: 8513865
[TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris.
Huang YS; Chen Z; Chen YQ; Ma GC; Shan JF; Liu W; Zhou LF
J Pept Sci; 2008 May; 14(5):588-95. PubMed ID: 17994612
[TBL] [Abstract][Full Text] [Related]
16. Expression, purification and characterization of recombinant human interleukin-2-serum albumin (rhIL-2-HSA) fusion protein in Pichia pastoris.
Lei J; Guan B; Li B; Duan Z; Chen Y; Li H; Jin J
Protein Expr Purif; 2012 Jul; 84(1):154-60. PubMed ID: 22609631
[TBL] [Abstract][Full Text] [Related]
17. [Purification and activity assay of HSA-AX15 (R13K) fusion protein expressed in Pichia pastoris].
Zhao HL; Xue C; Xiong XH; Zhang W; Yang BF; Liu ZM
Sheng Wu Gong Cheng Xue Bao; 2005 Mar; 21(2):254-8. PubMed ID: 16013485
[TBL] [Abstract][Full Text] [Related]
18. Enhanced sialylation of recombinant erythropoietin in genetically engineered Chinese-hamster ovary cells.
Jeong YT; Choi O; Son YD; Park SY; Kim JH
Biotechnol Appl Biochem; 2009 Apr; 52(Pt 4):283-91. PubMed ID: 18590515
[TBL] [Abstract][Full Text] [Related]
19. The effect of dissolved oxygen on the production and the glycosylation profile of recombinant human erythropoietin produced from CHO cells.
Restelli V; Wang MD; Huzel N; Ethier M; Perreault H; Butler M
Biotechnol Bioeng; 2006 Jun; 94(3):481-94. PubMed ID: 16523522
[TBL] [Abstract][Full Text] [Related]
20. Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor.
Makrides SC; Nygren PA; Andrews B; Ford PJ; Evans KS; Hayman EG; Adari H; Uhlén M; Toth CA
J Pharmacol Exp Ther; 1996 Apr; 277(1):534-42. PubMed ID: 8613964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
